Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
ZOFRAN / ZOFRAN ODT
Generic name / active ingredient
ondansetron
Dosage-form class
Conventional oral tablets, orally disintegrating tablets and 4 mg/5 mL oral solution must be identified separately. The 24 mg conventional tablet is an historical Orange Book product identity and is not listed among the available dosage forms and strengths in the current 2025 label
Route
Oral
Record reviewed
2026-08-29

Copy from the pack in hand

Source-linked reading points

  • Conventional tablets and ODTs may both say 4 mg or 8 mg, but their dosage form and handling differ. Keep ZOFRAN ODT in its blister until use, peel back the foil with dry hands, gently remove it rather than push the fragile tablet through the foil, and place it on the tongue immediately to dissolve. This is not an individual frequency or dosage-form switching rule.
  • ZOFRAN ODT contains aspartame and supplies a small amount of phenylalanine. A person with phenylketonuria or a caregiver should verify the exact form and current label; conventional-tablet or solution information does not replace this ODT ingredient warning.
  • The label warns about QT prolongation. Avoid use in congenital long-QT syndrome; low potassium or magnesium, congestive heart failure, bradyarrhythmia or another QT-prolonging medicine requires professional review and the label may call for ECG monitoring. Do not add, reduce, separate or stop any medicine from this page.
  • Serotonin syndrome may occur with serotonergic medicines, including some SSRIs, SNRIs, other antidepressants, triptans, tramadol, lithium, fentanyl and St John's wort. A combination of agitation, mental-status change, rapid heartbeat, blood-pressure change, fever, sweating, tremor, muscle rigidity or diarrhoea needs immediate medical assessment; use local emergency services if severe.

Reviewed presentation examples — compare every field

  • Ondansetron 4 mg per tablet; historical RLD currently listed as Discontinued in the Orange BookNDA 020103 / Product 001
  • Ondansetron 8 mg per tablet; historical RLD currently listed as Discontinued in the Orange BookNDA 020103 / Product 002
  • Ondansetron 24 mg per tablet; historical RLD currently listed as Discontinued in the Orange BookNDA 020103 / Product 003
  • Ondansetron 4 mg per orally disintegrating tablet; historical RLD currently listed as Discontinued in the Orange BookNDA 020781 / Product 001
  • Ondansetron 8 mg per orally disintegrating tablet; historical RLD currently listed as Discontinued in the Orange BookNDA 020781 / Product 002
  • Ondansetron 4 mg per 5 mL; this is a concentration, not an individual's millilitresNDA 020605 / Product 001

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-29
Source record
3 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image